This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A compound of the formula (Ia) or (Ib):



(Ia)

, or



(Ib)

or a pharmaceutically acceptable salt or tautomer thereof, wherein:

R^1 is an optionally substituted saturated, unsaturated, or aromatic C_3-C_{20} mono-, bi- or polycyclic ring optionally containing at least one heteroatom selected from the group consisting of N, O and S;

each R^3 is independently selected from the group consisting of: hydrogen, halo, halo(C_1-C_6)alkyl, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, perhalo(C_1-C_6)alkyl, (C_5-C_{10})heteroaryl, (C_5-C_{10})heterocycle, ~~(C_3-C_{10})heterocyclic,~~ (C_3-C_{10})cycloalkyl, hydroxy, (C_1-C_6)alkoxy, perhalo(C_1-C_6)alkoxy, phenoxy, (C_5-C_{10})heteroaryl-O-, (C_5-C_{10})heterocycle-O-, ~~(C_5-C_{10})heterocyclic-O-,~~ (C_3-C_{10})cycloalkyl-O-, (C_1-C_6)alkyl-S-, (C_1-C_6)alkyl-SO_2-, (C_1-C_6)alkyl-NH-SO_2-, nitro, cyano, amino, $Ph(CH_2)_{1-6}NH$-, (C_1-C_6)alkylamino, [(C_1-C_6)alkyl]$_2$-amino, (C_1-C_6)alkyl-SO_2-NH-, amino(C=O)-, aminoSO_2-, (C_1-C_6)alkyl-(C=O)-NH-, (C_1-

C_6)alkyl-(C=O)-[((C$_1$-C$_6$)alkyl)-N]-, phenyl-(C=O)-NH-, phenyl-(C=O)-[((C$_1$-C$_6$)alkyl)-N]-, (C$_1$-C$_6$)alkyl-(C=O)-, phenyl-(C=O)-, (C$_5$-C$_{10}$)heteroaryl-(C=O)-, (C$_5$-C$_{10}$)heterocycle-(C=O)-, ~~(C$_5$-C$_{10}$)heterocycle-(C=O)-~~, (C$_3$-C$_{10}$)cycloalkyl-(C=O)-, HO-(C=O)-, (C$_1$-C$_6$)alkyl-O-(C=O)-, H_2N(C=O)-(C$_1$-C$_6$)alkyl-NH-(C=O)-, [(C$_1$-C$_6$)alkyl]$_2$-N-(C=O)-, phenyl-NH-(C=O)-, phenyl-[((C$_1$-C$_6$)alkyl)-N]-(C=O)-, (C$_5$-C$_{10}$)heteroaryl-NH-(C=O)-, (C$_5$-C$_{10}$)heterocycle-NH-(C=O)-, ~~(C$_5$-C$_{10}$)heterocycle-NH-(C=O)-~~, (C$_3$-C$_{10}$)cycloalkyl-NH-(C=O)- and (C$_1$-C$_6$)alkyl-(C=O)-O-, where R^3 is optionally substituted by at least one substituent independently selected from (C$_1$-C$_6$)alkyl, (C$_1$-C$_6$)alkoxy, halo(C$_1$-C$_6$)alkyl, halo, H_2N-, Ph(CH$_2$)$_{1-6}$NH-, and (C$_1$-C$_6$)alkylNH-;

s is an integer from one to four ~~five~~; and

R^4 and R^6 taken together with the atoms to which they are attached form a core fused heteroaromatic.

2. (original) A compound of claim 1, wherein R^3 is a (C$_1$-C$_6$)alkyl or a (C$_3$-C$_{10}$)cycloalkyl group.

3. (original) A compound of claim 2, wherein R^3 is a methyl or a cyclopropyl group;

4. (currently amended) A compound of claim 1, wherein R^1 is



,


,


,





wherein R^{2a} is independently selected from the group consisting of: hydrogen, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, (C_3-C_{10})cycloalkyl, (C_5-C_{10})aryl, (C_1-C_6)alkyl(C_5-C_{10})aryl, amino, carbonyl, carboxyl, ~~(C_1-C_6)acid, (C_1-C_6)ester,~~ (C_5-C_{10})heteroaryl, (C_5-C_{10})heterocyclyl, (C_1-C_6)alkoxy, nitro, halo, and hydroxyl, ~~and (C_1-C_6)alkoxy(C_1-C_6)ester~~; and where alkyl, alkenyl, alkynyl, cycloalkyl, aryl, amino, heteroaryl, heterocyclyl, and alkoxy of R^{2a} is optionally substituted by at least one moiety independently selected from the group consisting

of hydrogen, halo, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, perhalo(C_1-C_6)alkyl, phenyl, (C_3-C_{10})cycloalkyl, (C_5-C_{10})heteroaryl, ~~(C_5-C_{10})heterocycle,~~ ~~(C_5-C_{10})heterocyclic,~~ formyl, -CN, (C_1-C_6)alkyl-(C=O)-, phenyl-(C=O)-, HO-(C=O)-, (C_1-C_6)alkyl-O-(C=O)-, (C_1-C_6)alkyl-NH-(C=O)-, $((C_1-C_6)alkyl)_2$-N-(C=O)-, phenyl-NH-(C=O)-, phenyl-[$((C_1-C_6)$alkyl)-N]-(C=O)-, nitro, amino, (C_1-C_6)alkylamino, $((C_1-C_6)alkyl)_2$-amino, (C_1-C_6)alkyl-(C=O)-NH-, (C_1-C_6)alkyl-(C=O)-[((C_1-C_6)alkyl)-N]-, phenyl-(C=O)-NH-, phenyl-(C=O)-[$((C_1-C_6)$alkyl)-N]-, H_2N-(C=O)-NH-, (C_1-C_6)alkyl-HN-(C=O)-NH-, $((C_1-C_6)alkyl)_2N$-(C=O)-NH-, (C_1-C_6)alkyl-HN-(C=O)-[$((C_1-C_6)$alkyl)-N]-, $((C_1-C_6)alkyl)_2N$-(C=O)-[(C_1-C_6)alkyl-N]-, phenyl-HN-(C=O)-NH-, $(phenyl)_2N$-(C=O)-NH-, phenyl-HN-(C=O)-[$((C_1-C_6)$alkyl)-N]-, $(phenyl)_2N$-(C=O)-[$((C_1-C_6)$alkyl)-N]-, (C_1-C_6)alkyl-O-(C=O)-NH-, (C_1-C_6)alkyl-O-(C=O)-[$((C_1-C_6)$alkyl)-N]-, phenyl-O-(C=O)-NH-, phenyl-O-(C=O)-[$((C_1-C_6)$alkyl)-N]-, (C_1-C_6)alkyl-SO_2NH-, phenyl-SO_2NH-, (C_1-C_6)alkyl-SO_2-, phenyl-SO_2-, hydroxy, (C_1-C_6)alkoxy, perhalo(C_1-C_6)alkoxy, phenoxy, (C_1-C_6)alkyl-(C=O)-O-, ~~(C_1-C_6)ester-(C_1-C_6)alkyl-O-~~, phenyl-(C=O)-O-, H_2N-(C=O)-O-, (C_1-C_6)alkyl-HN-(C=O)-O-, $((C_1-C_6)alkyl)_2N$-(C=O)-O-, phenyl-HN-(C=O)-O-, and $(phenyl)_2N$-(C=O)-O-; and

R^{2b} and R^{2c} taken together with the atoms to which they are attached form an optionally substituted mono-, bi- or polycyclic, saturated, unsaturated, or aromatic ring system optionally containing at least one heteroatom selected from the group consisting of N, O and S.

5.-12. (cancelled)

13. (previously presented) A compound selected from the group consisting of:
6-[2-(6-Methyl-pyridin-2-yl)-imidazo[1,2-a]pyrimidin-3-yl]-quinoline;
2-Benzo[1,3]dioxol-5-yl-3-(6-methyl-pyridin-2-yl)-imidazo[1,2-a]pyrimidine;
6-[3-(6-Methyl-pyridin-2-yl)-imidazo[1,2-a]pyrimidin-2-yl]-quinoline;
1-Methyl-6-[3-(6-methyl-pyridin-2-yl)-imidazo[1,2-a]pyrimidin-2-yl]-1H-benzotriazole;
6-[7-Methyl-2-(6-methyl-pyridin-2-yl)-imidazo[1,2-a]pyrimidin-3-yl]-quinoline;
2-(6-Methyl-pyridin-2-yl)-3-quinolin-6-yl-imidazo[1,2-a]pyrimidin-7-ylamine;
1-Methyl-6-[2-(6-methyl-pyridin-2-yl)-imidazo[1,2-a]pyrimidin-3-yl]-1H-benzotriazole;
2-Methyl-5-[2-(6-methyl-pyridin-2-yl)-imidazo[1,2-a]pyrimidin-3-yl]-2H-benzotriazole;

3-(2-Methyl-2H-benzotriazol-5-yl)-2-(6-methyl-pyridin-2-yl)-imidazo[1,2-a]pyrimidin-7-ylamine;

2-(6-Methyl-pyridin-2-yl)-3-quinolin-6-yl-imidazo[1,2-a]pyrimidin-7-ol;

Dimethyl-[2-(6-methyl-pyridin-2-yl)-3-quinolin-6-yl-imidazo[1,2-a]pyrimidin-7-yl]-amine;

2-(6-Methyl-pyridin-2-yl)-3-pyridin-4-yl-imidazo[1,2-a]pyrimidine;

2-(6-Methyl-pyridin-2-yl)-3-pyridin-4-yl-imidazo[1,2-a]pyrimidin-7-ylamine; and

3-Benzothiazol-6-yl-2-(6-methyl-pyridin-2-yl)-imidazo[1,2-a]pyrimidin-7-ylamine.

14. (original) A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

15. (cancelled)

16. (cancelled)